Guangzhou Jlh Biotechnology

Guangzhou Jialihua Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in Targeted Protein Degradation (TPD). The company utilizes its proprietary Proteolysis Targeting Chimera (PROTAC) platform to develop next-generation small molecule therapeutics for cancer and other serious diseases. Its lead clinical candidate, JLH-001, is a potent Androgen Receptor (AR) degrader designed to treat patients with metastatic castration-resistant prostate cancer who have failed standard hormonal therapies. Beyond its lead program, Jialihua is advancing a diverse pipeline of degraders targeting Bruton tyrosine kinase (BTK) and other high-value oncogenic proteins. The company was founded by leading scientists in the field of protein degradation and is backed by top-tier venture capital investors including Hillhouse Capital and IDG Capital.